Regeneron Pharmaceuticals, Inc. (REGN) – A diversified growth story

The company is experiencing high demand for REGEN COV, its COVID 19 therapy. The therapy, REGEN COV, have been authorized in the United States for treating non hospitalized COVID 19 patients and the companies signed supply deals with the U.S. government worth millions of dollars.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 38